Introduction: The urgent need for operational research evaluating test performance in a real-world setting has been highlighted. The purpose of this study was therefore to evaluate the performance of MTBDRplus assay.
Materials: According to the reference method, of the 155 clinical specimens with valid results, 147 were susceptible to rifampicin (RIF) and isoniazid (INH), with 4 being multi-drug resistant (MDR) and 4 with isolated resistance to isoniazid (INH).
Results: The results of the MTBDRplus assay were 100% concordant for the MDR and mono-resistant to INH specimens. However, the MTBDRplus assay showed a resistance pattern to RIF in one specimen which was classified as susceptible by the reference method. The majority of the specimens (118/75.6%) were also tested using the MTBDRplus method after culture on Lowenstein-Jensen media, showing 100% agreement with the results of the test directly from the specimens. An MTBDRplus test result was available within an average of 8 days.
Conclusions: Overall, MTBDR results showed excellent results when compared with the reference method and achieved a significant time-reduction.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.eimc.2014.02.017 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Diagnostic accuracy of Truenat MTB Plus, Truenat MTB Ultima and Xpert MTB/RIF Ultra for the diagnosis of pulmonary TB in an HIV-endemic setting.
Res Sq
September 2024
DSI-NRF Centre of Excellence for Biomedical Tuberculosis Research; South African Medical Research Council Centre for Tuberculosis Research; Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Article Synopsis
- Truenat MTB Plus and MTB Ultima are WHO-approved tests for tuberculosis, but their performance data are limited, prompting a study in Cape Town, South Africa with 498 participants.
- The study compared the accuracy of these tests against the Xpert MTB/RIF Ultra using culture as the reference standard, revealing sensitivities of 84% for MTB Plus, 90% for Ultima, and 92% for Ultra, with varying specificities.
- While Ultima showed similar sensitivity to Ultra, both tests had significant rates of unsuccessful results and exhibited variability based on lot differences, indicating that improvements are needed in their reliability for TB detection.
The performance of Xpert MTB/RIF and MTBDRplus within a Programmatic setting at TB Laboratory in Rio de Janeiro, Brazil.
Rev Soc Bras Med Trop
September 2024
Universidade Federal do Rio de Janeiro, Faculdade de Medicina, Programa Acadêmico de Tuberculose, Rio de Janeiro, RJ, Brasil.
Background: Few studies in routine settings have confirmed the high accuracy of the Xpert MTB/RIF assay for detecting rifampicin resistance (RR) and the first-line probe assay (FL-LPA) for detecting both RR and isoniazid resistance (INHR).
Methods: The performance of Xpert MTB/RIF and MTBDRplus VER 2.0 LPA was evaluated in 180 Mycobacterium tuberculosis samples collected from January 2018 to December 2019 in Rio de Janeiro, Brazil.
Diagnostic Accuracy of FluoroCycler XT MTBDR Assay for Detection of Rifampicin and Isoniazid-resistant Mycobacteria tuberculosis in Clinical Isolates from Kenya.
Int J Mycobacteriol
July 2024
National Tuberculosis Reference Laboratory, National Public Health Laboratories, Nairobi, Kenya.
Background: Drug-resistant tuberculosis (DR-TB) poses a major global challenge to public health and therapeutics. It is an emerging global concern associated with increased morbidity and mortality mostly seen in the low- and middle-income countries. Molecular techniques are highly sensitive and offer timely and accurate results for TB drug resistance testing, thereby positively influencing patient management plan.
View Article and Find Full Text PDFEvaluation of GeneNAT Real-Time Polymerase Chain Reaction Analyzer and Pre-loaded Chip-Based Mycobacterium tuberculosis and Multidrug-Resistant Tuberculosis Detection in the Diagnosis of Pulmonary Tuberculosis.
Cureus
July 2024
Internal Medicine, All India Institute of Medical Sciences, New Delhi, IND.
Background: Tuberculosis (TB) is still the second causative agent of death worldwide after COVID-19. It is caused by (MTB) infection.
Objective: The aim of the current study was to compare the performance of GeneNAT real-time polymerase chain reaction analyzer and pre-loaded chip-based MTB screening and multidrug-resistant tuberculosis (MDR-TB) detection kit (Smart Sure MTB & MDR-TB, Genetix Biotech Asia Pvt.
Molecular Epidemiology of Isoniazid-resistant in Port-au-Prince, Haiti.
Open Forum Infect Dis
August 2024
Center for Global Health, Weill Cornell Medicine, New York, New York, USA.
Background: Isoniazid-resistant, rifampin-susceptible tuberculosis (Hr-TB) is associated with poor treatment outcomes and higher rates of acquisition of further drug resistance during treatment. Due to a lack of widespread diagnostics, Hr-TB is frequently undetected and its epidemiology is incompletely understood.
Methods: We studied the molecular epidemiology of Hr-TB among all patients diagnosed with culture-positive pulmonary tuberculosis between January 1 and June 30, 2017, at an urban referral tuberculosis clinic in Port-au-Prince, Haiti.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!